LEMD3 as A Cancer Drug Target and Biomarker (G23592)

Target Name: LEMD3

NCBI ID: G23592

LEMD3

LEMD3 as A Cancer Drug Target and Biomarker

LEMD3 (Lipid-Enriched Extracellular Matrix-derived DNA3) is a protein that is expressed in various cell types, including human pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). It is derived from the extracellular matrix (ECM) of these cells and contain DNA, RNA, and proteins that are present in the ECM.

Recent studies have shown that LEMD3 is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the development and progression of various diseases, including cancer.

As a drug target, LEMD3 is a promising candidate for the treatment of various diseases, including cancer. Its potential benefits arise from its ability to regulate the growth, migration, and invasion of cancer cells, as well as its potential to promote apoptosis (programmed cell death) in cancer cells.

One of the key advantages of LEMD3 as a drug target is its ability to be targeted specifically to cancer cells. This is because LEMD3 is expressed in various cell types, including cancer cells, but is not found in non-cancer cells. This allows for a targeted delivery of LEMD3-based therapies to cancer cells, without the potential for unintended side effects in non-cancer cells.

Another advantage of LEMD3 is its potential to be used as a biomarker for cancer diagnosis and treatment. Because it could be used as a marker for the identification of cancer cells, as well as for the monitoring of the effectiveness of cancer therapies.

Additionally, LEMD3 has been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, LEMD3 has been shown to regulate the angiogenesis (the formation of new blood vessels) that is necessary for the growth and progression of cancer cells.

Furthermore, LEMD3 has also been shown to be involved in the regulation of the immune response. It has been shown to play a role in the regulation of T cell proliferation and differentiation, which is important for the immune response.

Overall, LEMD3 is a promising drug target and biomarker for the treatment of cancer. Its ability to be targeted specifically to cancer cells, as well as its potential as a biomarker, makes it an attractive candidate for further research.

Protein Name: LEM Domain Containing 3

Functions: Can function as a specific repressor of TGF-beta, activin, and BMP signaling through its interaction with the R-SMAD proteins. Antagonizes TGF-beta-induced cell proliferation arrest

The "LEMD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LEMD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets